Precipio, Inc. (PRPO)
| Market Cap | 40.35M +32.7% |
| Revenue (ttm) | 27.20M +28.0% |
| Net Income | -1.22M |
| EPS | -0.70 |
| Shares Out | 1.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 45,180 |
| Open | 22.24 |
| Previous Close | 22.25 |
| Day's Range | 22.00 - 22.81 |
| 52-Week Range | 16.40 - 33.63 |
| Beta | 1.30 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About PRPO
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Financial Performance
In 2025, Precipio's revenue was $24.05 million, an increase of 29.77% compared to the previous year's $18.53 million. Losses were -$363,000, -91.54% less than in 2024.
Financial StatementsNews
Precipio Earnings Call Transcript: Q2 2026
Q2 revenue exceeded $7M, up 22% YoY, while adjusted EBITDA turned positive and operating cash flow lifted cash to $3M without financing. Product revenue hit a record, and H2 focus is pipeline conversion and sustained operating leverage.
Precipio Quarterly report: Q2 2026
Precipio has published its Q2 2026 quarterly earnings report on August 17, 2026.
Precipio Earnings release: Q2 2026
Precipio released its Q2 2026 earnings on August 17, 2026, summarizing the period's financial results.
Precipio Announces Q2-2026 Financial Results
Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and stre...
Precipio Announces Q2-2026 Shareholder Update Call
NEW HAVEN, Conn., July 31, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at ...
Precipio Transcript: Planet MicroCap Las Vegas 2026
Profitability was achieved in Q3 2025, driven by a unique, rapid diagnostic platform and a shift toward high-margin products. The company targets significant market share in blood cancers, leveraging distributor partnerships and a scalable business model, with no customer attrition to date.
Precipio Slides: FY 2026
Precipio has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 17, 2026.
Precipio Transcript: AGM 2026
Shareholders approved the re-election of three directors for three-year terms and ratified the appointment of the independent auditor for 2026. All proposals passed, with results to be filed with the SEC.
Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting
NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote thei...
Precipio to Present at the Planet MicroCap Las Vegas
NEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on ...
Precipio Earnings Call Transcript: Q1 2026
Q1 2026 revenue was flat sequentially but up 30% year-over-year, with pathology growth offset by product shipment timing and an 8% CMS reimbursement cut. Commercial pipeline expanded to $10M, and margins are expected to recover as investments yield results.
Precipio Quarterly report: Q1 2026
Precipio has published its Q1 2026 quarterly earnings report on May 18, 2026.
Precipio Earnings release: Q1 2026
Precipio released its Q1 2026 earnings on May 18, 2026, summarizing the period's financial results.
Precipio reports Q1 revenue $6.71M vs $6.69M last year
“I think this quarter is a good example of how to properly assess non-commercial fluctuations in our business,” said Ilan Danieli, CEO of Precipio (PRPO). “While revenue is flat, that…
Precipio Announces Q1 2026 Financial Results
Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth Stable revenue performance driven by timing dynamics; expanding product pipeline e...
Management team's 2025 market-based Options have vested
NEW HAVEN, Conn., May 13, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that 2025 employee stock options granted to certain members of Precip...
Precipio Announces Q1-2026 Shareholder Update Call
NEW HAVEN, Conn., May 06, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) , will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00...
Precipio Proxy statement: Proxy filing
Precipio filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Precipio Proxy statement: Proxy filing
Precipio filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Precipio Earnings Call Transcript: Q4 2025
Achieved positive cash flow and 30% revenue growth in 2025, driven by Pathology Services and improved margins. Products Division poised for growth in 2026 with new commercial hires and scalable manufacturing, targeting a $500M addressable market.
Precipio Annual report: Q4 2025
Precipio has published its Q4 2025 annual report on April 2, 2026.
Precipio Announces Q4 and year-end 2025 Shareholder Update Call
NEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 20...
Precipio announces publication in Journal of Clinical Pathology
Precipio (PRPO) has announced the publication in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio’s new B...
Precipio reports FY25 revenue $24M vs. $18.5M last year
“Becoming an EBITDA and cash-flow positive business has a very important impact on how we manage the business. It allows us to now invest in growth projects that consider a…
Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year
In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M